Antengene Biologics Limited
Clinical trials sponsored by Antengene Biologics Limited, explained in plain language.
-
New drug ATG 022 targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called ATG 022 in about 156 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug can shrink tumors or …
Phase: PHASE1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated May 02, 2026 06:34 UTC
-
New hope for advanced stomach cancer: drug combo targets hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug (ATG-022) combined with pembrolizumab, with or without chemotherapy, in people with advanced stomach or gastroesophageal junction cancer that has spread and cannot be removed by surgery. The cancer must have a specific marker called CLDN18.2 and be neg…
Phase: PHASE1, PHASE2 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Apr 26, 2026 19:44 UTC